Compare Amphastar Pharmaceuticals Inc (AMPH) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while YieldMax MSTR Option Income Strategy ETF trades at $12.52. The key difference: Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMPH | MSTY | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $30.81 | $114.30 |
52-Week Low | $16.87 | $11.55 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
MSTY trades at $12.83, up 0.79% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF maintains a high distribution schedule, paying weekly dividends, though recent news highlights concerns over uncapped losses and NAV erosion. Support is clustered around $12-$13, with resistance just above the current price.
Outlook remains cautious due to structural risks from the covered-call strategy capping upside. High yield appeals to income seekers, but total return depends on preserving capital. Key risks include Strategy stock volatility and return-of-capital distributions undermining long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
